Microsatellite-stable (MSS) / mismatch-repair proficient (pMMR)
The 'normal' result on the mismatch-repair test: the tumour has intact DNA spell-checking and few mutations. It describes about 95% of metastatic colorectal cancers and means checkpoint inhibitors alone are unlikely to work.
The opposite of MSI-high/dMMR. MSS tumours have low mutational burden and few neoantigens, so PD-1 blockade produced almost no responses in colorectal cancer (KEYNOTE-016), and the immunotherapy revolution in dMMR colorectal and endometrial cancer (CheckMate 8HW, dostarlimab) has bypassed them. Making MSS colorectal cancer immune-responsive with combinations (botensilimab-balstilimab, KRAS inhibitors plus PD-1, cancer vaccines) is one of the field's biggest open problems. In endometrial cancer pMMR patients benefit less from adding immunotherapy to chemotherapy but still gain (RUBY, NRG-GY018).
Pages like this
not linked directly; found by shared links- IdeaMaking microsatellite-stable colorectal cancer immunotherapy-responsive
Shares Hot vs cold tumours, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Colorectal cancer.
- Key paperLe 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval
Shares CheckMate 8HW, Tumour mutational burden (TMB), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Colorectal cancer.
- IdeaWRN inhibitors: a second synthetic-lethal win for mismatch-repair cancers
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Endometrial cancer, Colorectal cancer.
- PersonAurélien Marabelle
Shares Tumour mutational burden (TMB), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
- IdeaA frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Endometrial cancer, Colorectal cancer.
- TermPD-L1 expression testing (22C3, SP142, SP263)
Shares Immuno-oncology (IO) and checkpoint blockade, Tumour mutational burden (TMB).
- IdeaA randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Endometrial cancer, Colorectal cancer.
- Key paperCAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Endometrial cancer, Colorectal cancer.